Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Non Operating Income (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Non Operating Income for 16 consecutive years, with -$7.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 1390.67% to -$7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.4 million through Dec 2025, down 3869.08% year-over-year, with the annual reading at -$8.8 million for FY2025, 61.46% down from the prior year.
  • Non Operating Income for Q4 2025 was -$7.5 million at Harvard Bioscience, down from -$365000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $2.8 million in Q4 2023, with the low at -$7.5 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$449950.0, with a median of -$339000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income surged 1217.99% in 2022, then tumbled 1390.67% in 2025.
  • Over 5 years, Non Operating Income stood at -$189000.0 in 2021, then soared by 1217.99% to $2.1 million in 2022, then surged by 34.31% to $2.8 million in 2023, then plummeted by 79.6% to $579000.0 in 2024, then crashed by 1390.67% to -$7.5 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$7.5 million, -$365000.0, and -$1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.